⌕
Radiopharm Theranostics · RADX · Nasdaq
Tenet — · insufficient data
Compare
$0.67−1.77%At close
$0.67−0.01 (−1.77%)
At close: Nov 19, 2026, 4:00 PM ET· Nasdaq · USD
Data under review. Our nightly checks found a problem in this company's reported figures on Oct 23, 2026, so we are not showing its score, ratios or statements for now. The figures come back after they pass the checks two nights in a row. The price and chart are live.

Radiopharm Theranostics (RADX) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● GlobeNewsWireNov 4, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Radiopharm Theranostics Announces Alignment with U.S. FDA on Single Pivotal Phase 3 Trial for RAD101 in Diagnosis of Brain Metastases

Single, multicenter Phase 3 imaging trial of approximately 280 patients with brain metastases designed to demonstrate sensitivity and specificity above prespecified performance thresholds…

● GlobeNewsWireNov 2, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Radiopharm Theranostics Reports Business Update

Phase 3 imaging trial of RAD101 in recurrent brain metastases from solid tumors expected to initiate in 1Q27 following successful end-of-phase 2 meeting with U.S. Food and Drug Administration…

● GlobeNewsWireSep 9, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal Adenocarcinoma

Positive safety and favourable biodistribution seen in all subjects dosed Imaging data in all evaluable pancreatic cancer patients demonstrated significant tumor uptake Data support the targeting potential of RAD301 and …

● GlobeNewsWireAug 26, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors

Doses first patient at 70 mCi dose of RV-01, the first radiopharmaceutical therapeutic developed in Company's joint venture with MD Anderson Cancer Center Doses first patient at 70 mCi dose of RV-01, the first radiopharm…

● Defense WorldAug 21, 2026 · 02:22 ET
Radiopharm Theranostics (NASDAQ:RADX) Trading Down 8.4% – What’s Next?

Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ: RADX - Get Free Report)'s share price traded down 8.4% during mid-day trading on Thursday. The stock traded as low as $2.23 and last traded at $2.29. 88,911 shares…

● GlobeNewsWireAug 20, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial

Advancing RAD202 Phase 1 trial to next dose level of 180mCi in patients with HER2+ advanced solid tumors Previous diagnostic study of RAD202 in ten HER2-positive breast cancer patients demonstrated clinical proof-of-conc…

No upcoming events in the feeds.

ANT24−6.6%
NVDA7−2.3%
FOX6−2.9%
AMD3−6.0%

Article counts from the last market-wide feed page, across every symbol we track and not just RADX · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.